Pippa Stevens of CNBC.com brings you the most important business news headlines. On today’s show, Meg Tirrell explains why the FDA and CDC have asked to stop administering Johnson & Johnson vaccines after six women developed a rare blood clot disorder. In addition, Kate Rogers explores why restaurants have trouble hiring workers as meals return.
FDA warns states to stop using J&J Covid vaccine after rare blood clotting problem affects 6 women, kills 1
The Food and Drug Administration on Tuesday called on states to temporarily stop the use of Johnson & Johnson’s Covid-19 vaccine “as a precaution,” after six U.S. women developed a rare blood clotting disorder that left a woman dead and another in critical condition.
“At this time, these adverse events appear to be extremely rare,” the FDA said in a joint statement with the Centers for Disease Control and Prevention. “The safety of the COVID-19 vaccine is a top priority for the federal government, and we take all reports of COVID-19 vaccination very seriously.”
All six cases occurred in women between the ages of 18 and 48, with symptoms occurring six to 13 days after receiving the shot. Doctors usually treat that type of blood clot with heparin, but health regulators have noticed that it could be dangerous in this case and have recommended a different treatment.
States rush to replace J&J vaccination programs after FDA recommends a break
More than a dozen states took action Tuesday to stop vaccination with the Johnson & Johnson coronavirus vaccine shortly after the Food and Drug Administration recommended discontinuing its use after reports of some women developed a rare blood clotting disorder. .
States, such as the FDA and the Centers for Disease Control and Prevention, have pointed out that they act with extreme caution, as more than 6.8 million doses of J&J vaccine have been injected and only six of the blood clotting cases have so far it has been reported.
J&J said in a statement that “there is no clear causal relationship” between the rare type of blood clots and the vaccine, adding that it is working closely with regulators to assess the data.
Bitcoin reaches a new historical record over $ 63,000 before the debut of Coinbase
Bitcoin hit a record high of $ 63,000 on Tuesday as investors waited for the highly anticipated debut of the Coinbase cryptocurrency exchange on the stock market.
The price of bitcoin rose to $ 63,236, according to Coin Metrics, before falling slightly to about $ 62,877. It has increased by about 5% in the last 24 hours. Ether, the second most valuable digital currency after bitcoin, also set a new record, rising to $ 2,230.
Coinbase will go public on Wednesday through a direct listing that could value the company at up to $ 100 billion – more than major trading venue operators such as the Intercontinental Exchange, the owner of the New York Stock Exchange. Crypto investors welcome the company’s debut on the stock market as a major milestone for the industry after years of skepticism from Wall Street and regulators.